II pretrattamento con ticlopidina nello stent coronarico è associato a significativa riduzione di eventi avversi. Dati dal trial EPISTENT

Translated title of the contribution: Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events. Data from the evaluation of platelets IIb/IIIa inhibitor for stenting (EPISTENT) trial

S. R. Steinhubl, S. G. Ellis, K. Wolski, A. M. Lincoff, E. J. Topol, S. De Servi

Research output: Contribution to journalArticlepeer-review

Translated title of the contributionTiclopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events. Data from the evaluation of platelets IIb/IIIa inhibitor for stenting (EPISTENT) trial
Original languageItalian
Pages (from-to)805-806
Number of pages2
JournalItalian Heart Journal Supplement
Volume2
Issue number7
Publication statusPublished - 2001

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this